Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors at 20 institutions in 8 countries.
Jesús Duque-AfonsoDepartment of Hematology/Oncology, Faculty of Medicine, University of Freiburg Medical Center, Freiburg, Germany. jesus.duque.afonso@uniklinik-freiburg.de.ORCID 0000-0002-8287-5673
Jürgen FinkeDepartment of Hematology/Oncology, Faculty of Medicine, University of Freiburg Medical Center, Freiburg, Germany.ORCID 0000-0002-1799-5927
Maud NgoyaEBMT Statistical Unit, INSERM UMRs 938, Hôpital Saint Antoine, Paris, France.
Jacques-Emmanuel GalimardEBMT Statistical Unit, INSERM UMRs 938, Hôpital Saint Antoine, Paris, France.ORCID 0000-0001-9102-4427
Charles CraddockBirmingham Centre for Cellular Therapy and Transplantation, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, UK.ORCID 0000-0001-5041-6678
Kavita RajDepartment of Haematology, University College London Hospital, London, UK.ORCID 0000-0002-8258-354X
Adrian BloorThe Christie NHS Foundation Trust, Stem Cell Transplantation Unit, University of Manchester, Manchester, UK.
Emma NicholsonDepartment of Haematology, Royal Marsden Hospital, London, UK.ORCID 0000-0002-6439-0795
Matthias EderDepartment of Haematology, Hannover Medical School, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany.
Orchard KimDepartment of Haematology, Southampton General Hospital, Haematology, Oncology & Paediatrics, Southampton, UK.
Thomas ValeriusDepartment of Medicine II, University Medical Center Schleswig-Holstein, Campus Kiel, Section of Stem Cell Transplantation and Immunotherapy, Kiel, Germany.ORCID 0000-0001-9181-8067
John A SnowdenDepartment of Hematology, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, UK.ORCID 0000-0001-6819-3476
Eleni TholouliClinical Haematology Department, Manchester Royal Infirmary, Manchester, UK.
Charles CrawleyDepartment of Haematology, Addenbrookes Hospital, Cambridge, UK.
Matthew CollinAdult HSCT unit, Northern Centre for Bone Marrow Transplantation, Freeman Hospital, Newcastle Tyne, UK.
Keith M O WilsonDepartment of Haematology, University Hospital of Wales, Cardiff, UK.ORCID 0000-0002-6327-9366
Alain GadisseurDepartment of Hematology, Antwerp University Hospital (UZA), Antwerp Edegem, Belgium.
Rachel ProtheroeUniversity Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Eva Maria Wagner-DrouetDepartment of Hematology, University Medical Center Mainz, Oncology and Pneumology, Mainz, Germany.ORCID 0000-0002-0728-2253
Bipin N SavaniDivision of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-3304-9965
Inserm · FRUniversity of Freiburg · DEAddenbrooke's Hospital · GBAntwerp University Hospital · BEFreeman Hospital · GBGeneral University Hospital of Patras · GRJohannes Gutenberg University Mainz · DEManchester Royal Infirmary · GBMedizinische Hochschule Hannover · DEQueen Elizabeth Hospital Birmingham · GBRoyal Hallamshire Hospital · GBRoyal Marsden Hospital · GBSheba Medical Center · ILSouthampton General Hospital · GBUniversity College Hospital · GBUniversity Hospital of Wales · GBUniversity Hospitals Bristol NHS Foundation Trust · GBUniversity of Manchester · GBVanderbilt University Medical Center · USVita-Salute San Raffaele University · IT
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Conditioning protocols for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) are being developed continuously to improve their anti-leukemic efficacy and reduce their toxicity. In this study, we compared the conditioning protocol of fludarabine with melphalan 140 mg/m
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party. · full record | OpenQuestion